Facebook
Twitter
LinkedIn
Forward
The Potassium Problem in Hemodialysis: Interprofessional Approaches to Hyperkalemia Management in ESRD
This Grand Rounds series is targeted to physician specialists in nephrology, cardiology, emergency medicine, and primary care, as well as pharmacists, nurses, nurse practitioners, and physician assistants who manage patients with ESRD.
Supported through an independent educational grant from AstraZeneca.
Target Audience
Specialists in nephrology, cardiology, emergency medicine, and primary care, as well as pharmacists, nurses, nurse practitioners, and physician assistants.
Learning Objectives
- Describe the pathophysiology of hyperkalemia in end stage renal disease (ESRD), especially in patients receiving hemodialysis, and discuss the immense morbidity and mortality implications of elevated predialysis K+ levels.
- Review traditional strategies for managing serum K+ in ESRD patients receiving dialysis and identify the pivotal shortcomings of these standard approaches.
- Examine novel pharmacologic treatment approaches for reducing the incidence of predialysis hyperkalemia, including an appraisal of completed and ongoing clinical trials and recent FDA approvals.
- Using a case-based format, apply evolving, interprofessional management strategies to prevent and manage hyperkalemia in ESRD patients receiving hemodialysis, with a focus on the promising role of K+ binders.
Additional Information
| Attachment | Size |
|---|---|
 General Info and Handout | 2.99 MB |
5 min Welcome and Introductions/Pre-test
10 min Hyperkalemia in Hemodialysis: Pathophysiology, Risk Factors, and Clinical Gravity
20 min A Paradigm Evolved: The Emerging Role of K+ Binders in End Stage Renal Disease
20 min Meeting Complexity with Collaboration: A Team-based Approach for Managing K+ in Dialysis Patients
5 min Conversations with the Experts/Q&A/Post-test
Ma
tthew R. Weir, MD
Director of the Division of Nephrology
Department of Medicine at the University of Maryland Hospital
Professor of Medicine at the University of Maryland School of Medicine
Baltimore, MD
Dr. Matthew R. Weir was named a "Top Doctor" in the specialty of Nephrology by Baltimore magazine in 2020. Dr. Weir is an attending physician and Director of the Division of Nephrology in the Department of Medicine at the University of Maryland Hospital, Baltimore. He is also a Professor of Medicine at the University of Maryland School of Medicine.
Dr. Weir's primary research interests include the use of antihypertensive therapy for the treatment of diabetic nephropathy, hypertensive renal injury in African Americans and preventing allograft nephropathy in transplant recipients. Special interests include cardiovascular disease associated with chronic kidney disease. He has written more than 450 manuscripts and book chapters about these topics. He has edited four books, including "Medical Management of Kidney Transplantation" and "Hypertension." He has presented at numerous international scientific association meetings, hospitals and medical schools.
Dr. Weir currently reviews manuscripts for more than 20 major medical journals, including the American Journal of Kidney Disease, the Journal of the American Society of Nephrology, and Archives of Internal Medicine. He is on the editorial board of ten journals and is Section Editor of Current Hypertension Reports and Current Opinion in Hypertension and Nephrology, and Associate Editor of Clinical Nephrology and the American Journal of Nephrology. He has three active NIH supported grants from NIDDK. In addition, he is a member of numerous associations, including the American Society of Nephrology, the National Kidney Foundation, the American Heart Association, and the American Society of Transplantation.
Dr. Weir received his medical degree from the University of Virginia, Charlottesville. He completed his internship and residency programs in Medicine at the Waterbury and Yale-New Haven Hospitals in Connecticut and completed his nephrology training at the Brigham and Women's Hospital, Harvard Medical School, in Boston, Massachusetts. He then moved to the University of Maryland where he has been a full-time faculty member since 1983.
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.
Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as an entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
PLANNERS
Estella Davis, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Csaba P. Kovesdy, MD–has disclosed that he is a consultant for AstraZeneca, Bayer, Cara Therapeutics, Reata, Takeda, and Tricida; receives grant/research support from Relypsa.
Barbara Odom BSN, RN, CDN–has no relevant financial relationships to disclose in relation to the content of this activity.
PRESENTERS
George Bakris, MD–has disclosed that he is a consultant for Alynlam, AstraZeneca, Bayer, Ionis, Merck, Novo-Nordisk, Janssen, Relypsa, and Vifor; receives grant/research support from Novo Nordisk and Vascular Dynamics.
Katherine E. Di Palo, PharmD, FAHA, FHFSA, BCACP, BCGP–has disclosed that she receives grant/research support from Vifor.
Csaba P. Kovesdy, MD– has disclosed that he is a consultant for AstraZeneca, Bayer, Cara Therapeutics, Reata, Takeda, and Tricida; receives grant/research support from Relypsa.
Matthew R. Weir, MD–has disclosed that he is a consultant for AstraZeneca, Bayer, Boehringer Ingelheim, Janssen, Merck, Novo Nordisk, and Vifor.
PEER REVIEWERS
Terri Cook, PharmD, BCPC, AACC–has no relevant financial relationships to disclose in relation to the content of this activity.
Debra K. Moser, PhD, RN, FAAN–has no relevant financial relationships to disclose in relation to the content of this activity.
Barry Wall, MD–has no relevant financial relationships to disclose in relation to the content of this activity.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1 hour of Interprofessional Continuing Education (IPCE) credit for learning and change.
Medicine (ACCME)
CEC designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacy (ACPE)
This application-based activity is approved for 1.0 contact hour (.10 CEUs) of continuing pharmacy education credit (JA0007101-0000-21-001-L01-P)
Nursing (ANCC)
This activity is designated for 1.0 contact hour.
Upon completion of a CE request form, statements of credit for physicians, physician assistants, and nurses will be issued within 30 business days. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy® (NABP®) CPE Monitor electronic CE tracking system.
Available Credit
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 IPCE
- 1.00 Participation